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Abstract
Background
The World Health Organization’s strategy to halve snakebite mortality and morbidity by
2030 includes an emphasis on a risk-benefit process assessing the preclinical efficacy of
antivenoms manufactured for sub-Saharan Africa. To assist this process, we systematically
collected, standardised and analysed all publicly available data on the preclinical efficacy of
antivenoms designed for sub-Saharan Africa.
Methodology/Principal findings
Using a systematic search of publication databases, we focused on publicly available pre-
clinical reports of the efficacy of 16 antivenom products available in sub Saharan Africa.
Publications since 1999 reporting the industry standard intravenous pre-incubation method
of murine in vivo neutralisation of venom lethality (median effective dose [ED50]) were
included. Eighteen publications met the criteria. To permit comparison of the several differ-
ent reported ED50 values, it was necessary to standardise these to microlitre of antivenom
resulting in 50% survival of mice challenged per milligram of venom (μl/mg). We were
unable to identify publicly available preclinical data on four antivenoms, whilst data for six
polyspecific antivenoms were restricted to a small number of venoms. Only four antivenoms
were tested against a wide range of venoms. Examination of these studies for the reporting
of key metrics required for interpreting antivenom ED50s were highly variable, as evidenced
by eight different units being used for the described ED50 values.
Conclusions/Significance
There is a disturbing lack of (i) preclinical efficacy testing of antivenom for sub Saharan
Africa, (ii) publicly available reports and (iii) independent scrutiny of this medically important
data. Where reports do exist, the methods and metrics used are highly variable. This
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prevents comprehensive meta-analysis of antivenom preclinical efficacy, and severely
reduces the utility of antivenom ED50 results in the decision making of physicians treating
patients and of national and international health agencies. Here, we propose the use of a
standardised result reporting checklist to resolve this issue. Implementation of these
straightforward steps will deliver uniform evaluation of products across laboratories, facili-
tate meta-analyses, and contribute vital information for designing the clinical trials needed to
achieve the WHO target of halving snakebite morbidity and mortality by 2030.
Author summary
Antivenom is the first-choice therapy for victims of snakebite envenoming. Currently
there is very little robust evidence that the antivenoms currently being used in Africa are
suitable or effective. Unusually for a human medicine, clinical trials are not a pre-requisite
for antivenom approval, licensing and use in patients. This leaves a situation where nearly
all the information of an antivenom’s effectiveness is based on mouse assays assessing
neutralisation of venom-induced lethality, so-called “preclinical” antivenom testing. Here
we analysed all the publicly available preclinical data on antivenoms for Africa published
in the last 20 years. Our results demonstrate that there is worryingly little publicly avail-
able information on the preclinical efficacy of antivenoms and that the efficacy of some
products is seemingly very weak. We hope that the World Health Organization’s anti-
venom assessment and listing scheme (independently and systematically testing anti-
venom efficacy and quality) will fill many of these crucial information gaps. Furthermore,
the quality of the result reporting was highly variable across studies, making meaningful
comparisons difficult and causing challenges for clinicians treating snakebites to rapidly
decipher efficacy information. To remedy this, we have developed a reporting checklist to
harmonise preclinical antivenom efficacy reporting across the globe.
Introduction
Snakebite envenoming (SBE) is a Neglected Tropical Disease that annually kills 85,000–
130,000 and maims >400,000 people living in the world’s most disadvantaged communities
[1,2]. The lack of safe, effective antivenoms in many parts of the tropics is the main driver of
the continuing high mortality and morbidity rates observed in these regions. The World
Health Organization (WHO) has identified the supply of safe and effective treatments as one
of four key objectives to halve SBE mortality and morbidity by 2030 [3].
Antivenom (purified polyclonal immunoglobulin from venom-immunised animals) is the
first-choice therapy for SBE. Due to the method of manufacture, antivenom effectiveness is
largely restricted to the venom/s used for animal immunisation [4,5]. Differences in venom
composition can vary substantially between species, and even between different locales of the
same species [6–8]. The geographic origin of venom immunogens can therefore influence the
geographic effectiveness of antivenoms [9].
Antivenoms are atypical therapeutics since they have often been deployed for human use
without undergoing traditional Phase 1, 2 and 3 clinical testing [10]. A recent review of the
clinical effectiveness of antivenoms for sub-Saharan Africa identified that only three of the
antivenoms currently used in Africa are supported by robust clinical trial data [11]. In the
absence of robust clinical trials, the small number of good-quality clinical reports (primarily
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prospective observational cohort studies or retrospective analyses) suggest the effectiveness of
many products is limited. As further observed by Potet et al, no robust and reliable clinical
information is available for seven antivenoms currently in use in sub-Saharan Africa [11].
Thus in many countries, in the absence of clinical data, the preclinical neutralisation of
venom lethality in a mouse model is seemingly the only antivenom efficacy data required
before a product is registered and used clinically [10]. Due to the absence or paucity of inde-
pendently generated preclinical information for many antivenoms, it is often the manufactur-
er’s results of preclinical efficacy, which are very rarely published, that form the only basis of
decision making. This means antivenoms are often deployed without robust, independently-
scrutinised, preclinical or clinical evidence of their efficacy or effectiveness—sometimes with
fatal consequences [11–14]. A tragic 2008 example of this was the reported increase in mortal-
ity of antivenom-treated patients from 1.8% to 12.1% following the introduction into West
Africa of an antivenom manufactured with venom from Indian snakes [12]. Recent publica-
tions indicate that this still not uncommon [13,14]. Consequently, efforts are urgently required
to better assist and simplify the decision making of physicians treating snakebite patients, and
of government and other medicine-procuring agencies [3].
The WHO recommends that preclinical testing of antivenoms follows a two-step process; a
preliminary in vitro assessment followed by essential in vivo preclinical analyses [10]. The pre-
liminary in vitro approach (e.g. using methods such as ELISA, immunoblotting [15] or antive-
nomics [16]) is primarily to identify antivenoms which are likely to lack efficacy during
essential in vivo assays, and are thus crucial to reducing the number of animals required for
testing.
Following adequate preliminary in vitro assessment, antivenoms must be assessed via the
standard assay of preclinical efficacy testing; the in vivo murine antivenom “neutralisation of
venom lethality” or “median effective dose (ED50)” assay (for the original description of the
assay see [17] and for a detailed review of the assay see [18,19]). The assay is performed by mix-
ing a fixed dose of venom that induces death in 100% of mice (usually 2.5–5.0 fold the median
lethal dose [LD50]–the amount of venom that kills 50% of injected mice) with varying volumes
of antivenom, and intravenously (IV–although some practitioners use the intraperitoneal
route) injecting this into mice following a 30 minute incubation step at 37 oC. Survival of
injected mice after a specified time interval (usually 24 hours) are recorded and data analysis is
used to calculate the ED50—the dose of antivenom that results in survival of 50% of injected
mice.
Increasing the availability and transparency of available information on antivenom preclin-
ical efficacy can contribute to validating manufacturer claims, provide independent assessment
of efficacy, and aid regulatory bodies and health care providers to make informed choices.
This is reflected by the fact that the WHO, prior to a stock-piling initiative, is currently under-
taking an assessment and listing of antivenoms for sub-Saharan Africa [3]. It is hoped that
such an assessment will identify products with favourable “risk–benefit ratios”, and thus aid
health agencies and other relevant stakeholders to make informed decisions on antivenom
procurement. We hope this valuable evidence will be made available for scrutiny by the wider
SBE community–in particular to those designing clinical trials.
However, lack of international consensus in preclinical antivenom testing has the potential
to threaten this approach. Inadequate and non-standardised reporting of the results of animal
research is a major contributor to poor experimental reproducibility and prevents harmonisa-
tion of results for meta-analyses. Addressing these issues for murine antivenom-efficacy exper-
iments will help provide the evidence needed to guide clinical trial and clinician decision
making. In this context, the 2011 ARRIVE (Animal Research: Reporting of In Vivo Experi-
ments) guidelines provide protocols to improve animal reporting and experimental
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reproducibility [20]. Since publication, the ARRIVE guidelines have been endorsed by >1000
international journals, research institutes and funders [21] but their uptake by individual
research groups and enforcement by many journals has been relatively poor [22].
Here, using the ARRIVE guidelines as a basis for comparison, we assess the extent to which
current reporting of preclinical antivenom efficacy results across studies presents the informa-
tion required to allow thorough scrutiny and understanding of results presented, and how
adoption of standardised reporting of results will increase the value of data that can be
obtained. Furthermore, we aim to provide information that will assist researchers, clinicians
and health agencies, and to identify areas in which future preclinical antivenom research needs
to be focused and those that need urgent improvement in the interim. To that end, we investi-
gated all ED50 antivenom-efficacy publications of snakebite therapeutics used in sub-Saharan
Africa in the past 20 years.
Methods
Definitions
Several key terms are used throughout this manuscript which we wish to define to aid
comprehension.
Median lethal dose (LD50): the quantity of snake venom that leads to the death of 50% of the
animals in a group after an established period of time [10].
Median effective dose (ED50): the quantity (expressed as a ratio of μl antivenom per mg of
venom) of antivenom that protects 50% of test animals injected with a lethal dose (typically
2.5–5 x LD50) of venom [10]. Alternatively, this can be viewed as the quantity of antivenom
that neutralises all but 1 x LD50.
Efficacy: the efficacy of an antivenom is a measure of the in vivo or in vitro neutralising
potency against a specific activity of a venom or venoms [10].
Effectiveness: the effectiveness of an antivenom is a measure of its ability to produce a clini-
cally effective outcome when used to treat snakebite envenoming [10].
Monospecific/monovalent antivenom: Raised from the venom of a single species and are lim-
ited in use to that species or to a few closely related species.
Polyspecific/polyvalent antivenom: Raised from a mixture of venoms from more than one
species of venomous snake.
Antivenoms
We focussed our assessment on the same 16 antivenoms that featured in the valuable recent
assessment of the clinical effectiveness and safety of antivenom treatment of snakebite victims
in sub-Saharan Africa [11] (Table 1). We recorded details on the preclinical efficacy of each
antivenom using data from product packaging or inserts provided by each manufacturer.
Publication search strategy
We searched for publications relating to any of the 16 antivenom products listed in Table 1 on
PubMed, Web of Science and Scopus. The keywords “Antiven� and Africa” or “Anti-snake�
and Africa” or “ASV and Africa” or “Anti-ophidic and Africa”, were used in association with:
i) “ED50” or ii) “LD50” or iii) “Preclinical” or iv) individual product names (a full list of search
terms and papers returned can be found in S1 and S2 Files, respectively). As availability of
individual antivenom brands in sub-Saharan Africa has changed dramatically within the last
twenty years (products being withdrawn and new products entering the market), results were
limited to publications since 1999. Only results representing neutralisation of lethality
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experiments (ED50) via the intravenous route and performed in mice were included. Only
papers in English, French, Spanish and Portuguese were included. An initial search was per-
formed on 2nd of August 2019 followed by a second search on 11th May 2020 (note, access to
Scopus was unavailable on this occasion).
Standardisation of values and assessment of the quality of reporting
For each publication that met the criteria for inclusion, we recorded whether each study
reported the basic details required for interpreting ED50s. To do this, we assessed the identified
publications against four main criteria adapted from recommendations of the ARRIVE guide-
lines for in vivo reporting [20].
Experimental set up: The assessment criteria were: i) Details of venom supplier. ii) Geo-
graphical origin of the snake venom(s). iii) Details of antivenom(s) used including source,
Table 1. Commercially available, or recently available, African antivenom products. This table is based on estimation of available antivenom products by Potet et al.
2019 [11]. � = manufacturing currently on hold.
Antivenom brand name Manufacturer Country of
production
Species venoms neutralized according to product insert Animal
Source
Type of Ig
fragment
Antivipmyn-Africa Instituto Bioclon
(Silanes)
Mexico B. arietans, B. gabonica, B. rhinoceros, D. angusticeps, D. jamesoni, D.
polylepis, D. viridis, E. leucogaster, E. ocellatus, E. pyramidum, N.
haje, N. katiensis, N. melanoleuca, N. nigricollis, N. nivea
Equine F(ab)’2
ASNA antivenom C Bharat Serum and
Vaccines
India B. arietans, B. gabonica, B. nasicornis, D. angusticeps, D. jamesoni, D.
polylepis, E. carinatus, N. haje, N. melanoleuca, N. nigricollis N. nivea
Equine F(ab)’2
ASNA antivenom D
(ASNA-D)
Bharat Serum and
Vaccines
India B. arietans, B. gabonica, B. nasicornis, D. angusticeps, D. jamesoni, D.
polylepis, E. ocellatus, N. haje, N. melanoleuca, N. nigricollis, N. nivea
Equine F(ab)’2
EchiTAbG MicroPharm United
Kingdom
E. ocellatus Ovine IgG
EchiTAb-Plus-ICP Instituto Clodomiro
Picado
Costa Rica B. arietans, E. ocellatus, N. nigricollis Equine IgG
Fav-Afrique� Sanofi-Pasteur France B. arietans, B. gabonica, D. jamesoni, D. polylepis, D. viridis, E.
leucogaster, E. ocellatus, N. haje, N. melanoleuca N. nigricollis
Equine F(ab)’2
Inoserp
Pan Africa
Inosan Mexico/
Spain
B. arietans, B. gabonica, B. rhinoceros, D. angusticeps, D. jamesoni, D.
polylepis, D. viridis, E. leucogaster, E. ocellatus, E. pyramidum, N.
haje, N. katiensis, N. melanoleuca, N. nigricollis, N. nivea, N. pallida
Equine F(ab)’2
Snake Venom Antiserum
(Pan Africa)
Premium Serums India B. arietans, B. gabonica, B. nasicornis, B. rhinoceros, D. angusticeps, D.
jamesoni, D. polylepis, D. viridis, E. carinatus, E. leucogaster, E.
ocellatus, N. nigricollis, N. haje, N. melanoleuca
Equine F(ab)’2
Snake Venom Antiserum
(Central Africa)
Premium Serums India B. rhinoceros, E. carinatus, D. russelli, D. polylepis Equine F(ab)’2
SAIMR Boomslang South African
Vaccine Producers
South Africa D. typus Equine F(ab)’2
SAIMR Echis South African
Vaccine Producers
South Africa E. carinatus, E. ocellatus, E. coloratus, Cerastes spp. Equine F(ab)’2
SAIMR Polyvalent South African
Vaccine Producers
South Africa B. arietans, B. gabonica, D. angusticeps, D. jamesoni, D. polylepis, H.
haemachatus, N. annulifera, N. melanoleuca, N. mossambica, N. nivea
Equine F(ab)’2
Snake Venom Antiserum
Polyvalent (equine)
VACSERA Egypt B. arietans, B. gabonica, C. cerastes, C. vipera, E. carinatus, E.
coloratus, M. lebetina, M. palestinae, N. haje, N. melanoleuca, N.
mossambica, N. nigricollis, N. oxiana, P. persicus,V. ammodytes, V.
xanthina, W. aegyptia
Equine F(ab)’2
VINS Snake Venom
Antiserum (Central
Africa)
VINS Bioproducts India B. gabonica, E. carinatus, D. russelli, D. polylepis Equine F(ab)’2
VINS Snake Venom
Antiserum (Echis)
VINS Bioproducts India E. ocellatus Equine F(ab)’2
VINS Snake Venom
Antiserum (Pan Africa)
VINS Bioproducts India B. arietans, B. gabonica, D. jamesoni, D. polylepis, D. viridis,
E. leucogaster, E. ocellatus, N. haje, N. melanoleuca, N. nigricollis
Equine F(ab)’2
https://doi.org/10.1371/journal.pntd.0008579.t001
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batch and expiry date. iv) Antivenom total protein content (in mg total protein/ml of anti-
venom) and the method by which it was determined. v) Ethical compliance statement. vi)
Conflict of interest statement.
Animals: The assessment criteria were: i) Source of animals. ii) Strain. iii) Weight. iv) Sex.
v) Basic husbandry details.
Procedure: The assessment criteria were: i) Stating of control groups. ii) Number of animals
per group. iii) Total number of animals and number of groups used. iv) Multiples of LD50 used
to determine ED50. v) If and how antivenom was pre-incubated with venom. vi) Route of
administration. vii) Injection volume. viii) Experiment duration.
Result reporting: The assessment criteria were: i) Mouse group outcome reporting. ii) Pres-
ence or absence of adverse events. iii) Description of statistical analysis. iv) Units used to
describe ED50s.
Due to the various metrics of antivenom efficacy used in these reports, and to enable cross-
comparison of the results, all ED50 values were standardised to the dose of antivenom, in
microlitres, which prevents lethality in 50% of test mice per milligram of venom (μl/mg)–a rec-
ommend metric detailed in the WHO guidelines[10]. Calculations used for conversions are
available in S3 File. All statistical analyses were performed using GraphPad Prism 5.
Results
Summary
The database search returned a total of 505 publications (S2 File). Only 18 publications met
our criteria for inclusion: murine studies published since 1999 that described the standard
assay of preclinical neutralisation of venom lethality using any of the 16 antivenoms indicated
for envenoming by African snake species.
In total, the preclinical efficacy of these African antivenoms against venoms from 29 snake
species (Fig 1A) sourced from only 11 different African countries (Fig 1B) were examined.
Two venoms were designated as originating from “North” or “East Africa”, whilst the origin of
35 venoms was not stated.
Of the 16 antivenoms available (historically and/or contemporarily) in sub-Saharan Africa,
12 had preclinical data publicly available, and a complete list of the summarised, standardised
ED50 and potency values for each can be found in S1 Table. Worryingly, we could not find any
published evidence for the preclinical efficacy of the ASNA antivenom D (Bharat Serum and
Vaccines, India), Premium Snake Venom Antiserum (Central Africa) (Premium Serums,
India), VINS Snake Venom Antiserum (Echis) (VINS Bioproducts, India) and SAIMR Boom-
slang (South African Vaccine Producers, South Africa) antivenoms (although alternative
methods of determining preclinical efficacy have been applied to the SAIMR Boomslang prod-
uct [23]).
There exists little publicly available data relating to the efficacy of the majority of polyspeci-
fic antivenoms, with each examined against one to six venoms (Table 1), including VINS
Snake Venom Antiserum (Pan Africa) (VINS Bioproducts, India), VINS Snake Venom Anti-
serum (Central Africa) (VINS Bioproducts, India), Inoserp (Pan Africa) (Inosan, Spain/
Mexico), Premium Snake Venom Antiserum Pan Africa (Premium Serums, India) and ASNA
antivenom C (Bharat Serum and Vaccines, India), some of which are widely available in sub-
Saharan Africa and indicated to treat envenoming by multiple snake species. Conversely, poly-
specific antivenoms Antivipmyn-Africa (Instituto Bioclon [Silanes], Mexico), Snake Venom
Antiserum Polyvalent (equine) (VACSERA, Egypt), herein referred as “VACSERA”, SAIMR
Polyvalent (South African Vaccine Producers, South Africa) and trivalent antivenom Echi-
TAb-Plus-ICP (Instituto Clodomiro Picado, Costa Rica) were tested against multiple snake
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Fig 1. Summary of breadth and frequency of publicly available preclinical testing data of available African antivenoms vs. medically important snakes of the
region. a) The heat map represents the number of times each antivenom has been tested against a venom. x = antivenom manufacturer makes specific claims of
neutralisation against this venom. + = antivenom manufacturer makes specific claims of para-specific neutralisation against this venom (i.e. venom not used as an
immunogen). # = manufacturer has claimed this venom is used for immunisation during antivenom manufacture. Antivenom names as in Table 1. b) The geographical
origin of the snake venoms used in prior preclinical studies of African antivenom efficacy. The darker the blue colour, the more venoms that were investigated from that
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species’ venoms (21, 13, 14 and 15 different venoms, respectively) (Table 1). The efficacy data
for Antivipmyn-Africa, VACSERA and EchiTAb-Plus-ICP was near exclusively supplied from
laboratories associated with the antivenom manufacturers.
Six studies reported antivenoms lacking preclinical efficacy against one or more snake ven-
oms (S1 Table), but the majority of these concerned venoms that were either not used in man-
ufacture (where stated) or for which the antivenoms are not indicated for (e.g., EchiTAb-Plus-
ICP vs. D. polylepis, N. annulifera, H. haemachatus, N. katiensis, N. mossambica and N. nubiae
[24]; VINS Snake Venom Antiserum (Central Africa) vs. D. angusticeps [25] and ASNA anti-
venom C vs. N. annulifera, N. mossambica and H. haemachatus [26]). This emphasises the gen-
eral species specificity of antivenoms. VINS Snake Venom Antiserum (Pan Africa) was the
only antivenom described as lacking efficacy against a venom for which it is indicated for (E.
ocellatus [27]).
There was a statistically significant trend (unpaired t-test with Welch’s correction,
P = 0.002) of antivenoms possessing more efficacious mean ED50 values against viper venoms
(n = 67, mean: 1021.0 μl/mg, Std. Deviation [SD]: ±1411 μl/mg, range: 14.90–8333.0 μl/mg)
than elapid venoms (n = 49, mean: 1884.0 μl/mg, SD: ±1469.0 μl/mg, range: 175.4–6061.0 μl/
mg) indicating that relatively more viper venom is neutralised per ml of antivenom (Fig 1C). It
is tempting to speculate that this observation may be the result of viper venoms typically being
dominated by higher molecular mass proteins [28] (and thus more immunogenic), than typi-
cally low molecular mass dominated (e.g. <14 kDa three finger toxin and phospholipase A2
family) elapid venoms. SAIMR Polyvalent is a notable exception to this observation, demon-
strating consistently more-efficacious anti-elapid (and more anti-viper-like) ED50s, compared
to other polyvalent antivenoms (Fig 1C, Fig 2, S1 File). This could be due to the exceptionally
high total protein concentration in to SAIMR Polyvalent (Fig 1D), which is typically 2–3 times
greater than that of other similar products. Alternatively, immunisation strategies can substan-
tially affect the efficacy of resulting antivenoms [29,30], and we encourage antivenom manu-
facturers to be more transparent with their immunisation strategies such that these factors can
be carefully evaluated and thereby enabling their adoption by other manufacturers.
Antivenom efficacy against viper venoms
Saw-scaled vipers (Echis spp.): Unsurprisingly, due to its medical and economic impact in
West Africa [31], the efficacy of antivenoms against the venom of Echis ocellatus (west African
saw-scaled viper) was investigated more than any other snake species (30 individual experi-
ments using nine different antivenoms, Fig 1A). Antivenoms demonstrating preclinical effi-
cacy against E. ocellatus venom exhibited ED50 values ranging from just 75.2 μl/mg to
2173.9 μl/mg, with a mean of 706.3 μl/mg (SD ±556.2 μl/mg) across all studies (Fig 2A, S1
Table). The least efficacious ED50 value reported for E. ocellatus (above) was determined using
EchiTAbG (Micropharm, U.K.) [32], which also was reported in another study to have a
potent preclinical efficacy of 80.8 μl/mg [33], an almost 27 fold difference. These studies were
performed using different antivenom batches, in different laboratories and using venom
sourced from distinct regions—Mali and Nigeria, respectively—and thus may account for the
large differences in observed preclinical efficacy. However, the minimum preclinical efficacy
country. Countries without colour did not have any venoms represented in the preclinical testing in the identified studies. c) The preclinical efficacy of African
antivenoms against venoms from vipers and elapids (see S1 Table for species classification, individual values and references). ED50 values represented as dose of
antivenom, in μl, which prevents lethality in 50% of test mice per mg of venom (μl/mg). Significance (P) determined using an unpaired t test with Welch’s correction. d)
Total protein content of African antivenoms in this study. Bold bar represents the mean, whiskers represent standard deviation of the mean. Values and references
supporting this data are available in S2 Table. Bars represent standard deviation of the mean, and n.d. indicates not determined/available.
https://doi.org/10.1371/journal.pntd.0008579.g001
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of EchiTAbG appears sufficient for acceptable clinical efficacy based on positive outcomes
from one of the very few antivenom clinical trials performed to date [34]. EchiTAb-Plus-ICP
was tested eight times against E. ocellatus venom across five studies and provided more consis-
tent mean ED50 values (ranging from 216.9 to 350.9 μl/mg); although these experiments were
likely performed in the same laboratory (S1 Table). EchiTAb-Plus-ICP was also shown to be
clinically effective in clinical trials against Nigerian E. ocellatus [34]. The ED50 of VINS Snake
Venom Antiserum (Pan Africa) vs. E. ocellatus was examined once and determined to be
greater than 4000 μl/mg, a value which the authors decided demonstrated a lack of preclinical
efficacy against E. ocellatus venom [27]. Despite this, VINS Snake Venom Antiserum (Pan
Africa) is currently indicated for use for treating envenoming by this species (Table 1). We are
unable to determine if this particular product has been altered to improve efficacy since this
2016 report due to the lack of independent scrutiny. SAIMR Echis (South African Vaccine
Producers, South Africa), an antivenom which has a long association with good treatment out-
comes for African Echis envenoming [11,35,36], was examined preclinically twice against E.
ocellatus venom from Nigeria, providing highly efficacious ED50s of 131.3 μl/mg [33] and
75.2 μl/mg [37]). Notably, SAIMR Polyvalent (South African Vaccine Producers, South
Africa), an antivenom which is not indicated for the treatment of E. ocellatus, as this venom is
not including in the immunising mixture, was found to have preclinical efficacy against E. ocel-
latus envenoming in the single study in which it was tested, although the resulting ED50 value
was relatively lower compared to other products (934.1 μl/mg) [38]. The preclinical efficacy of
the polyvalent-pan African Inoserp (Pan Africa) antivenom has been examined three times
against E. ocellatus with higher than average ED50s of 1886.8 to 885.0 μl/mg (Fig 2A, S1 Table).
The efficacy of African antivenoms against the venom from other African species of saw-
scaled viper (e.g. E. leucogaster, E. pyramidum leakeyi, E. coloratus) has been explored to a
much lesser extent than E. ocellatus (Fig 1A). Five antivenoms exhibited broadly similar ED50
values against these Echis venoms as compared to E. ocellatus (S1 Table, Fig 2A), and included
EchiTAbG (E. coloratus and E. p. leakeyi [4]), EchiTAb-plus-ICP (E. leucogaster and E. p. lea-
keyi [39]), Fav-Afrique (Sanofi-Pasteur, [France]) (E. leucogaster [38]), SAIMR Echis (E. p. lea-
keyi [15]) and SAIMR Polyvalent (E. leucogaster [38]). The VACSERA antivenom was only
tested against E. coloratus and E. carinatus venoms (presumably E. p. leakeyi, which was histor-
ically named E. carinatus) from Sudan, providing weakly efficacious ED50 values of 3333.3 and
2222.2 μl/mg, respectively [40].
African adders (Bitis spp.): The preclinical efficacy of antivenoms against venom from the
puff adder (Bitis arietans), a large bodied medically important viper distributed widely across
sub-Saharan Africa, was examined fourteen times in seven studies (Fig 1A). The ED50 values
ranged enormously, from 3571.4 μl/mg (VACSERA) [40] to 14.9 μl/mg (SAIMR Polyvalent)
[41](S1 Table). However, the majority of reported ED50s values (10/14) ranged from 393.0 to
215.5 μl/mg.
Few studies examined the preclinical efficacy of antivenoms against venoms from other
medically important Bitis species, with only four antivenoms being tested, all of which were
paraspecific to the venom in question (i.e. the venom-immunising mixture used to generate
these antivenoms did not include venoms from these other Bitis species, or were not indicated
for neutralisation of these venoms) (Fig 1A, Table 1). In general, and as perhaps expected, the
resulting ED50 values demonstrated a greater quantity of these antivenoms are preclinically
Fig 2. The preclinical efficacy (ED50 values) of African antivenoms vs. a) viper venoms and b) neurotoxic elapid venoms and cytotoxic elapid venoms. Note difference
in axis scales. Values represented as dose of antivenom, in μl, which prevents lethality in 50% of test mice per mg of venom (μl/mg). Bars are 95% confidence intervals.
Where available, venom origin is named by country. Data reference is in square brackets. All data is additionally listed in S1 Table. Antivenom names are as in Table 1
with the following exceptions: ET-Plus-ICP = EchiTAb-Plus-ICP. PA = Pan Africa. CA = Central Africa. Poly = Polyvalent. NS = not specified.
https://doi.org/10.1371/journal.pntd.0008579.g002
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required against other Bitis species venoms as compared to B. arietans (range 395.0 to
1129.8 μl/mg for B. gabonica, 645.0 to 792.8 μl/mg for B. rhinoceros) (Fig 2A and S1 Table).
Antivipmyn-Africa was reported as lacking preclinical efficacy against B. nasicornis venom [5]
and EchiTAb-Plus-ICP also had poor efficacy (1639.0 μl/mg, S1 Table) against this venom
[39]. No data were available for any of the four antivenoms that are marketed with specific
claims of effectiveness against B. gabonica venom (VINS Snake Venom Antiserum [Pan
Africa], VINS Snake Venom Antiserum [Central Africa], Fav-Afrique and Premium Snake
Venom Antiserum [Pan Africa]) (Table 1).
Antivenom efficacy against neurotoxic elapid venoms
Mambas (Dendroaspis spp.): Eight antivenoms were examined for their preclinical efficacy
against D. polylepis (black mamba) venom (Fig 1A, Fig 2B). This snake is widely distributed
throughout sub-Saharan Africa and its venom causes rapid systemic neurotoxicity. All tested
antivenoms, with the exception of SAIMR-Polyvalent and EchiTAb-Plus-ICP, had ED50 values
for D. polylepis ranging from 1030.9 to 5000.0 μl/mg. It is noticeable that these ED50 values are
of considerably lower efficacy than those reported for the vipers described above (E. ocellatus,
mean 706.3 μl/mg; B. arietans, mean 664.4 μl/mg). Of all antivenoms assessed, SAIMR Polyva-
lent exhibited the most efficacious ED50 values against D. polylepis venom (190.1–448.0 μl/
mg), suggesting that this antivenom neutralises venoms from vipers and elapids with compara-
ble efficacy (S1 Table, Fig 2B). EchiTAb-Plus-ICP, unsurprisingly, lacked efficacy in neutralis-
ing D. polylepis venom, as no mamba venoms are used in the immunising mixture[26].
Data on the preclinical efficacy of antivenoms against related green mamba species (genus
Dendroaspis) were worryingly lacking (Fig 1A, Fig 2B). Four antivenoms were tested against
D. angusticeps. Antivipmyn-Africa and VINS Snake Venom Antiserum (Central Africa) are
not indicated for use against this species (Table 1) and neither possessed preclinical efficacy in
neutralising venom-induced lethality at the doses tested (S1 Table)[5,25]. The VINS Snake
Venom Antiserum (Pan Africa) and SAIMR Polyvalent antivenoms were examined in a single
D. angusticeps-venom study and exhibited ED50s of 416.7 and 250.0 μl/mg, respectively. Pre-
clinical efficacy of neutralisation of D. viridis venom was examined only once, where Antivip-
myn-Africa exhibited an ED50 of 2850.0 μl/mg [5]; of substantial lower efficacy compared to
other mamba venoms. We did not identify a single study reporting antivenom efficacy against
D. jamesoni (of either subspecies) venom.
Cobras (Naja spp.): The other medically important neurotoxic elapids distributed across
Africa are all members of the cobra genus Naja. With the exception of SAIMR Polyvalent, the
majority of the antivenoms examined demonstrated generally weak (1111.1–5952.4 μl/mg)
preclinical neutralising efficacies against neurotoxic cobra venoms (S1 Table).
Six antivenoms were tested for their preclinical efficacy against the venom of the snouted
cobra (N. annulifera) (Fig 1A, Fig 2B). SAIMR Polyvalent, the only antivenom with specific
claims for neutralising this venom, exhibited the most efficacious ED50 value (555.6 μl/mg, S1
Table)[26]—considerably lower ED50 values than obtained using the Antivipmyn-Africa and
Fav-Afrique antivenoms (1700.1 and 1111.1 μl/mg, respectively)[5,26]. Three antivenoms
(ASNA antivenom C, EchiTAb-Plus-ICP and Premium Snake Venom Antiserum [Pan
Africa]) failed to demonstrate preclinical efficacy against the venom of N. annulifera at the
doses tested (S1 Table)[26].
Despite its broad geographical distribution, only three antivenoms have been tested for
their neutralisation of N. haje (Egyptian cobra) venom: VACSERA, SAIMR Polyvalent and
Antivipmyn-Africa (Fig 1, Fig 2B). Although all three antivenoms prevented preclinical
venom-induced lethality in mice, the ED50 values demonstrated poor efficacy (1742.3–
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5952.4 μl/mg) (Fig 2B, S1 Table)[5,15,40]. Similar ED50 values were reported for Antivipmyn-
Africa, VACSERA and Fav-Afrique antivenoms against the venom of the forest cobra, N. mela-
noleuca (1778.8–2777.8 μl/mg) (Fig 2B, S1 Table)[5,38,40]. Two of three antivenoms (Antivip-
myn-Africa and SAIMR Polyvalent) tested against N. nivea (cape cobra) venom, demonstrated
efficacy in preventing venom-induced lethality in mice, although SAIMR Polyvalent was four
times more efficacious (2115.2 vs. 529.9 μl/mg, respectively)[5,42] (Fig 2B, S1 Table). The
VACSERA antivenom lacked preclinical efficacy in neutralising N. nivea venom at the doses
tested[40] (S1 Table).
Antivenom efficacy against cytotoxic elapid venoms
Cobras (Naja spp.) and rinkhals (Hemachatus haemachatus): Despite their medical importance
[43,44], their widespread distribution[24,45] and the specific claims of ten products to be effective
at neutralising envenoming of the predominately cytotoxic venoms of spitting cobras (Table 1),
very few antivenoms have been scrutinised for their preclinical efficacy against the venoms of
Naja nigricollis, N. pallida, N. mossambica or N. nubiae. Just four products (Antivipmyn-Africa,
EchiTAb-Plus-ICP, SAIMR Polyvalent and VACSERA) have been tested against N. nigricollis
venom (Fig 1A, Fig 2B, S1 Table) (although VINS Snake Venom Antiserum [Pan Africa], Inoserp
Pan Africa and Premium Snake Venom Antiserum [Pan Africa] have been examined for their
efficacy vs. N. nigricollis venom in a non-standard lethality assay[15]). EchiTAb-Plus-ICP was
examined three times against N. nigricollis venom, resulting in ED50 values of 781.3, 2000.0 and
1428.6 μl/mg [24,46]. Antivipmyn-Africa and SAIMR Polyvalent demonstrated similar efficacies
against this venom (1237.1 and 1133.9 μl/mg, respectively[5,15]). VACSERA demonstrated weak
preclinical efficacies of 6060.6 and 3571.4 μl/mg against N. nigricollis venoms from Egypt and
Sudan, respectively[40] (S1 Table). However, the former snake species may actually be N. nubiae,
as the geographical distribution of N. nigricollis does not extend into Egypt.
The above four antivenoms had publicly available data on their preclinical efficacy against
the venom of the East African spitting cobra species, N. pallida (Fig 1A, Fig 2B). Akin to the N.
nigricollis results, Antivipmyn-Africa and SAIMR Polyvalent antivenoms exhibited similar
ED50 values to one another (1761.9 and 1582.8 μl/mg, respectively[5,15]). EchiTAb-Plus-ICP
(with N. nigricollis but not N. pallida in the venom-immunising mixture) demonstrated
weaker efficacy (2631.6 μl/mg) against N. pallida[24] venom than against N. nigricollis venom
(see above and Fig 1). The ED50 value of the VACSERA product against N. pallida venom
(5494.5 μl/mg [40], S1 Table) was similar to that against N. nigricollis venom, above.
Reports of the preclinical efficacy of six antivenoms against the venom of the Mozambique
spitting cobra (N. mossambica) yielded highly variable results (Fig 2B). Neither EchiTAb-Plus-
ICP nor ASNA antivenom C antivenoms possessed efficacy in neutralising the preclinical lethal
effects of N. mossambica venom from eSwatini (formerly Swaziland)[26] (S1 Table). However,
EchiTAb-Plus-ICP did possess preclinical efficacy in neutralising N. mossambica venom
sourced from Tanzania (1515.2 μl/mg)[26] (S1 Table, Fig 2B), while Antivipmyn-Africa had a
preclinical neutralising efficacy of 1193.8 μl/mg [5] against N. mossambica venom of unknown
origin. VACSERA possessed weak preclinical efficacy (2631.6 μl/mg) against N. mossambica
venom similarly of unknown origin[40]. The efficacies of Fav-Afrique and SAIMR-Polyvalent
antivenoms against N. mossambica venom were both of greater preclinical efficacy (both
714.3 μl/mg) than any of the other combinations of antivenom and spitting cobra venom[26].
Although not a Naja species, the rinkhals (H. haemachathus) is a closely related elapid
snake species that spits venom, and envenoming exerts a predominately cytotoxic syndrome
[47]. Four antivenoms (Antivipmyn-Africa, Premium Snake Venom Antiserum (Pan-Africa),
SAIMR Polyvalent and Fav-Afrique) were shown to possess preclinical efficacy against H.
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haemachatus venom (Fig 2B, S1 Table), with SAIMR Polyvalent, the only antivenom indicated
for this venom in the immunising mixture (Table 1), being the most efficacious (ED50
175.4 μl/mg). Antivipmyn-Africa, Premium Snake Venom Antiserum (Pan-Africa) and Fav-
Afrique possessed much lower efficacies of 1097.1, 1250.0 and 666.7 μl/mg, respectively[5,26].
Neither EchiTAb-Plus-ICP nor ASNA antivenom C possessed preclinical efficacy required to
neutralise the lethal effects of H. haemachatus venom in mice (S1 Table)[26].
The quality of in vivo parameter reporting
To assess the quality of reporting of in vivo ED50 experiments, we assessed the extent to which
the data described in the 18 antivenom efficacy studies communicated the essential animal
experimental parameters against 24 criteria guided by ARRIVE recommendations. We defined
four areas of ED50 experiment reporting that would enable critical interpretation of results,
protocol reproducibility and harmonisation of results from multiple reports: “Experimental
setup”, “Animals”, “Procedure” and “Result reporting” (Table 2, S4 File). No single publication
achieved the basic reporting requirements described under these criteria, and we found vast
differences in reporting of the basic parameters of ED50 experiments (detailed in Table 2).
Experimental set up: Antivenom batches were reported by the majority (72%) of studies, as
was the geographic origin of the venom(s) used to test antivenom efficacy (94%). Reporting of
antivenom concentration, a key parameter when considering efficacy, was poor (Table 2). Half
of the 18 studies did not provide the total protein concentration of the antivenoms tested,
despite several reporting ED50s as milligrams of venom per milligram of antivenom (a com-
piled table of available total antivenom concentrations can be found in S2 Table). Where anti-
venom concentrations were reported, these ranged from 19 mg/ml to 171 mg/ml (Fig 1D, S3
Table).
Basic ethics statements were mentioned by most publications (78%), although only 11%
met the level of transparency recommended by ARRIVE guidelines[20] (e.g. confirming com-
pliance with all relevant ethical regulations and providing the name(s) of the board and institu-
tion that approved the study protocol). Conflict of interest statements were included for 61%
of the studies (Table 2). Although we noted one instance of a study stating no conflict of inter-
ests despite employees of the antivenom manufacturer being authors on the manuscript[5].
Animals: Most manuscripts describing ED50 experiments reported the strain of mice used
(88%), but two did not (Table 2). The majority of studies (77%) used the CD1 mouse strain,
one study used BALB/c and another used Swiss albino. All but one article (94%) reported the
weights of animals used (range 16-22g, majority 18-20g [14 of 18 studies]). The sex of the mice
used was often not stated (66% failed to report), but for those that did we noted considerable
variation, including the use of female, male or both sexes. Information on the husbandry of the
mice was only reported in a single article[48].
Procedure: The LD50 value used to calculate the resulting ED50 potencies was reported by
94% of papers. The range of venom LD50 doses used to assess ED50 values ranged from 2x
LD50 to 5x LD50, with the highest of this dose range the most frequently implemented (56% of
studies, Table 2). Whilst the number of animals per group was routinely reported (range 4–6,
mode = 5), the total number of groups or total number of animals used for experimentation
was not reported by any study. Pre-incubation of venom-antivenom mixtures (78%), the route
of injection (94%) and injection volumes (83%) were mostly well reported (although notable
exceptions raise concerns over study reproducibility). The experiment length was reported by
all but two papers, and was either 7 (22%), 24 (38%) or 48 (28%) hours (Table 2).
Result reporting: Eight different units for reporting ED50 values were presented (Table 2).
The WHO recommended[10] units of: (i) mgs of venom neutralised per ml of antivenom (mg/
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ml), (ii) μl antivenom required to neutralise the “challenge dose” of venom (μl /mouse), or (iii)
μl of antivenom required to neutralise 1 mg of venom (μl/mg), were used by 39%, 22% and
11% of publications, respectively. However, we note that the term “neutralised” in the WHO
guidelines recommended definitions is ambiguous and possibly unhelpful, as it provides the
impression that all venom is “neutralised” by the antivenom dose, which is not the case. A fur-
ther five different approaches to define ED50 were used in 28% of the studies analysed here.
The majority of publications reported on the statistical method used to calculate the ED50s -
most commonly Probit (50%) or Spearman Kaber (33%)—although two studies did not.
Standalone descriptions of in vivo statistical analysis were lacking in 72% of publications. The
use of 95% confidence intervals alongside ED50 values were included in 89% of studies
(Table 2). Finally, group outcome reporting was not provided in any study–this data is critical
for future analysis and interpretation of results, especially in the case of extremely large confi-
dence intervals. No paper reported the presence or absence of non-venom toxin mediated
adverse effects/events in the experimental animals. Such adverse events do occasionally occur,
particularly in the case of some antivenoms with high protein concentrations, where anti-
venom-venom mixtures produce observable precipitates (presumably the result of antibody/
venom complexes) which can subsequently cause death in injected mice [15].
Finally, errors that can hamper interpretation of results (incorrect units and mislabelling in
results tables) were identified in two manuscripts. We implore reviewers to pay extra attention
to all ED50 values being reported, the methodology used, and to query dubious results.
Discussion
Antivenoms are unusual human medicines because they are released for clinical use without
seemingly needing to undergo the rigorous regulatory frameworks and expectations required for
other drugs (e.g., clinical trials and transparent public access to data obtained regarding product
efficacy [49,50]). This anomaly likely reflects historical and prevailing lack of national and interna-
tional investment in snakebite management and regulatory frameworks pertaining to serothera-
pies. As a consequence, results from murine preclinical efficacy assays have become the primary
means to assess/predict antivenom performance. However, because the tropical countries that
most need antivenom rarely possess the requisite antivenom preclinical testing facilities, and
because of the lack of independent tests, an over-reliance upon manufacturer’s product claims has
evolved. In this study we (1) evidence and identify the risks posed by this situation and suggest
remedial actions, (2) describe how the data provided by 18 carefully-selected publications of pre-
clinical antivenom efficacy testing can be useful to decision making by clinical, medicines-regula-
tory agency, manufacturing and academic stakeholders, and (3) call for greater investment in
preclinical and clinical testing of antivenoms before they are released for human use.
1. The risks inherent to the variation in current antivenom preclinical
testing protocols and their reporting
The lack of publicly available data. There is no requirement for antivenom manufactur-
ers to publish their preclinical testing results. The expertise to rigorously scrutinise this data
can be lacking in the drug regulatory agencies of resource-poor countries that most need effec-
tive antivenom. Similarly, clinicians treating snakebite patients, especially those without snake-
bite management experience, can struggle to use the documentation accompanying a vial of
antivenom to make confident/accurate clinical decisions [15,51]. Academic groups have tried
to fill this knowledge gap. This study, however, has revealed a disturbing lack of published data
of the preclinical efficacy for antivenom products used in sub-Saharan Africa in the last 20
years. Notable gaps include:
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• published data for the majority of polyspecific African antivenoms is only available for a sub-
set of the venoms that they claim to neutralise (Fig 1A)
• there exists almost no publicly available reports on the preclinical efficacy or clinical effec-
tiveness [11] for some of the more affordable and widely-available antivenoms [15,51].
• the most comprehensive antivenom preclinical testing reports (wherein efficacy against a
large variety of venoms were examined) emanated from standalone studies which involved
the antivenom manufacturer [5,40]
While neutralisation of venoms from most of the medically important snakes of Africa
(e.g., E. ocellatus saw-scaled viper, D. polylepis black mamba) have been tested for more than
one antivenom and on more than one occasion (Fig 1A), we were unable to find a single pre-
clinical testing publication for many WHO category 1 (highest medical importance) species
including D. jamesoni, N. anchietae, N. ashei, N. katiensis, N. nigricincta, N. senegalensis and E.
jogeri.
These knowledge-gap examples highlight the urgent need for national and international
communities to (i) invest in the delivery of thorough preclinical testing of antivenom products
and (ii) ensure the results of these studies are made publicly available. These gaps in preclinical
data need to be addressed urgently to avoid the clinical use of inappropriate antivenoms that
have led to dramatic increases in case fatality rates[12,13] and to inform antivenom clinical
trial designs[3].
The quality of preclinical testing data. The variant ED50 protocols and efficacy metrics
employed by different laboratories in their publications (Table 2) limits opportunities for meta
analyses. This is further compounded by some laboratories using the intraperitoneal route of
injection to assess antivenom efficacy (which have not been considered here). Furthermore,
the ongoing reproducibility crisis in animal research [52] undoubtedly applies to preclinical
antivenom efficacy research. This is especially important given the current reliance on this
data for approving antivenoms for human use [10]. The examples below evidence some of
these inconsistencies and their potential impact:
i. Differences in venom LD50 values used to determine antivenom ED50s values for the
same species:
• The reports of ED50 values for E. ocellatus venom-neutralisation used 2 [38], 3 [5] and 5
(all remaining studies) times the venom LD50 dose. The ED50s for B. arietans were
reported using 3 [5,41] and 5 (majority of studies) times the venom LD50 doses, or not
stated at all [40]. The majority of ED50 values reported for Antivipmyn-Africa were
obtained using 3 x LD50s [5] (S1 Table).
• This is important, as the higher the challenge dose, the lower the estimation of preclinical
efficacy [18,53]. For example, Bogarin et al.[54] demonstrated that ED50 values of 163.9,
310.6 and 500.0 μl/mg were obtained for the same antivenom when tested against 3, 4 or 5
Bothrops asper venom LD50s, respectively.
Insufficient consideration of the venom challenge dose used in different effective median
dose experiments can mask important information on an antivenom’s efficacy. We therefore
recommend an international, species-specific consensus is agreed on the number of venom
LD50s used for measuring preclinical antivenom efficacy. For sub-Saharan African venoms, we
propose a 5 x venom LD50 dose in the majority of cases, with exemptions where high venom
LD50s values limit the amount of antivenom that can be administered [15].
ii. Differences in ED50 metrics and their confidence intervals:
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• Eight different preclinical efficacy metrics were used across the 18 studies investigated here
(Table 2). To undertake the cross-antivenom analysis reported here, we needed to convert
all the individual metrics into the μl/mg metric.
• Some studies reported ED50s with very large confidence intervals (Fig 2, S1 Table). For
example, for SAIMR Polyvalent against B. arietans, the sample mean ED50 in one study
was given as 373.2 μl/mg [37], however, based on the 95% confidence intervals (106.1–
561.6 μl/mg), the true mean efficacy could be as low as 106.1 μl/mg. Thus, this antivenom
might be 3.5-fold more potent than described. Conversely, the ED50 of ASNA antivenom
C for neutralising B. arietans venom was reported as 263.2 μl/mg [26], but the 95% confi-
dence intervals (200.0–666.7 μl/mg) suggest the population mean could be as high as
666.7 μl/mg, and thus the product may be more than 50% less potent than suggested.
While large confidence intervals are likely partially unavoidable due to the complex patho-
physiology of envenoming (where death often results from a multitude of cardiovascular
and/or haemostatic effects, such as shock or intercranial haemorrhage[55]), they may also
be due to attempting to calculate ED50 values with insufficient data (through use of insuffi-
cient animals (<4) per, or number of, groups). The resulting high range of some confi-
dence intervals risks inaccurate estimation of an antivenom’s preclinical efficacy.
This situation is clearly far from desirable, for all the reasons stated above, and especially
because of the potential over-estimation or under-estimation of an antivenom’s efficacy. Whilst
the WHO guidelines for antivenom preclinical efficacy testing suggest three metric options [10],
we argue that it is only through the standard use of a single metric that these reports can be useful
to clinicians, clinical trial designers and regulatory agencies–and we propose the use of the dose of
antivenom that protects 50% of mice per mg of venom (μl/mg) in all reports (with use of other
metrics as secondary descriptors left to the authors’ discretion). Whilst not the most frequently
used metric for describing antivenom efficacy (11% of the identified studies) (Table 2), our rea-
sons for selecting this particular metric are: i) it is easily understandable for people unfamiliar
with the assay to identify antivenoms that possess greater efficacy without the requirement for
additional information, and ii) it is within keeping of the pharmacological definition of effective
dose (e.g. a dose or concentration of a drug that produces a defined response).
The original intention of Theakston and Reid’s (1983) standardised preclinical test of anti-
venom efficacy [17] was to enable antivenoms to be “graded easily and uniformly, in terms of
their venom neutralising abilities, by different laboratories”–this is currently not being
achieved. To help facilitate standardisation of reporting of preclinical antivenom efficacy
experiments, we have developed an experimental reporting checklist (S4 File), guided by
ARRIVE recommendations, primarily for use in publishing antivenom preclinical testing in
academic journals. The criteria therein are the same as we used to assess the publications in
this paper (Table 2). We welcome ideas and suggestions to improve this document, and once
agreement has been reached with others in the community, we recommend that it be added to
the WHO guidelines for the production, control and regulation of snake antivenom
immunoglobulins.
We estimate that 3,930 mice were used to generate the results of the 18 publications exam-
ined here (excluding mice required to estimate venom LD50s doses). Whilst ‘cost-to-mice/ben-
efit-to-human health’ considerations undeniably justify these murine experiments, especially
in the absence of routine clinical trials, these assays are severe in nature and are distressing for
animals and researchers alike. In-line with recommendation in the WHO guidelines [10], we
urge the adoption of refined antivenom preclinical testing protocols, such as: the use of analge-
sia [56], dose staging [15], humane endpoints [23] and reduced experimental time [4], after a
period of careful validation.
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Issues posed by the geographical origin of venoms used for preclinical testing. Venom
content can vary substantially from region to region [8]. For example, the protein composition
of B. arietans venoms are known to exhibit geographical variation [6], and this species may
well represent a species complex. Similarly, N. melanoleuca was recently taxonomically reclas-
sified into five species[57], with unknown implications regarding venom protein composi-
tions. However, very few antivenoms have been preclinically tested on venoms from the same
species sourced from different geographical locales (Fig 1B, Fig 2, S1 Table). The notable
exceptions being EchiTAbG and EchiTAb-Plus-ICP for E. ocellatus and SAIMR Polyvalent for
B. arietans and, to a lesser extent, D. polylepis. We therefore advise against assuming that the
preclinical efficacy of an antivenom against a venom from one region can be simply extrapo-
lated to other regions. The dangers of such assumptions are apparent from the variable preclin-
ical efficacy of Russell’s viper (Daboia russelii) antivenoms manufactured with venom sourced
from India against venoms from Bangladesh, Pakistan and Sri Lanka [7].
Our analysis illustrates that venoms used for preclinical testing have tended to be sourced
from regional “hot spots” (Fig 1B). This results in an absence of antivenom efficacy data for
large swathes of sub-Saharan Africa, particularly central and southern countries suspected of
having substantial snakebite burdens [58,59]. It is therefore important that the scientific com-
munity expands preclinical testing of antivenoms to include venoms from different medically-
relevant regions. We also implore antivenom manufacturers to be more transparent on the ori-
gins of the venoms used in their immunisation procedures and subsequent assessments of pre-
clinical efficacy [19].
2. Use of the data provided by the 18 selected publications to inform
decision making
The very limited data on the clinical effectiveness of African antivenoms [3,11,60] has enforced
a reliance upon preclinical efficacy data to assess an antivenom’s potential clinical utility. The
results presented in Fig 2A identify that several of the antivenoms possess comparable preclini-
cal efficacy against B. arietans (puff adder) venom. The five studies reporting the highest effi-
cacy against E. ocellatus (saw-scaled viper) venom included the Echis monovalent, SAIMR
Echis and EchiTAbG antivenoms and the trivalent EchiTAb-Plus-ICP antivenom. Several
antivenoms exhibited comparable preclinical efficacy against the lethal effects of a variety of
spitting cobra venoms, but the clinical value of this is questionable because human envenom-
ing by these species rarely results in fatalities (see below). The SAIMR Polyvalent antivenom
showed markedly and consistently higher preclinical efficacy against venoms of the neurotoxic
cobras (N. haje, N. melanoleuca. N. nivea) and the black and green mambas (D. polylepis, D.
angusticeps) than any other single product.
Based on very limited human clinical evidence [11], African antivenoms with high ED50
doses should be treated with caution when considering their ability to neutralise envenoming
clinically. For example, Antivipmyn-Africa demonstrates ED50s of 1694.9–2850.0 μl/mg against
neurotoxic elapids (Table 1), and thus this antivenom is ‘efficacious’ preclinically, albeit with
low efficacy. However, very limited investigations into this antivenom’s clinical effectiveness
have suggested it works poorly against D. polylepis envenoming (Antivipmyn-Africa vs. D. poly-
lepis ED50 = 1694.9 μl/mg) [11,61]. While we must extrapolate with caution, given that many
antivenoms possess similarly high ED50 dose values as Antivipmyn-Africa against neurotoxic
venoms (S1 Table, Fig 2), any potential clinical effectiveness of such products against neurotoxic
snake venoms should be carefully evaluated before advocating for their widespread use.
Systemic life-threatening envenoming is not the only consequence of snakebite. Many
more victims per year suffer from the debilitating local effects of snake venoms. Thus, the
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continued marketing of antivenoms solely on the basis of their efficacy in neutralise systemic
lethal effects of envenoming is an ongoing concern [18]. Envenoming by cytotoxic elapids,
such as N. nigricollis, N. pallida and N. mossambica, primarily inflict substantial local necrosis
[62–64] and not the lethal systemic neurotoxic effects that are the primary measure of ED50
testing of elapid venoms [62]. Additionally, vipers such as the Bitis and Echis genera cause
extensive local necrosis in addition to systemic pathologies [55,62]. As recommended by the
WHO [10], preclinical examination of antivenom using the Minimum Necrotizing Dose
(MND) assay is required in addition to the ED50 assay to provide a more comprehensive analy-
sis of an antivenom’s efficacy. In this study, of the 16 papers detailing antivenom efficacies
against venoms inflicting local pathology (S1 Table), just two articles included results of MND
efficacies [24,39]. Thus, in the absence of evidence of preclinical efficacy of an antivenom in
the MND assay, alongside the total absence of clinical trials for any antivenom against African
spiting cobras, ED50 values should be considered with extreme caution when interpreting their
use for treating envenomation from African spitting cobras.
The challenge of extrapolating antivenom dose from preclinical data. There is a lack of
international consensus on the acceptable limits for the preclinical efficacies of antivenoms
other than the concept that they must prevent the most relevant toxic activities. An antivenom
that is unable to preclinically prevent venom-induced lethality in vivo should clearly not be
accepted for clinical use. However, as evidenced by the example of Antivipmyn-Africa vs. D.
polylepis, above [11,61], just because an antivenom can preclinically neutralise venom toxicity
in a murine model (e.g. at any ED50 value), does not mean that this product will be an effective
snakebite therapy in clinical settings. An antivenom must not be labelled as preclinically effica-
cious just because it can neutralise a venom at any ED50 value. Several reported ED50 values
collated in this study are poor and fall short of some of the preclinical efficacy cut off thresh-
olds employed by different researchers [5,24–26]. Whilst the use of such minimum ED50 effi-
cacy thresholds is controversial[19], common sense should prevail.
Furthermore, ED50 values need to be interpreted on a species-specific basis. Similar ED50
values from the same antivenom against two different snake species does not mean that the
antivenom will be equally effective against bites by both species in clinical settings. The ED50
potency is ultimately determined against a challenge dose of venom based on the species-spe-
cific LD50 value, thus the quantity of venom required to achieve a challenge dose varies sub-
stantially between species and within species from different locations (S2 Table). Perhaps most
importantly, these analyses do not consider the amount of venom which can be delivered dur-
ing a snake bite, which can vary from less than 10 mg (e.g. mean venom yields of E. p. leakeyi
and E. ocellatus reported as 7.4[±2.6] and 10.2[±4.9] mg) to routinely greater than 150 mg of
venom (e.g. mean yields of B. arietans and N. nigricollis reported as 166[±76.0] and 159.7
[±86.2] mg, respectively)[65].
Ultimately, the final proof of antivenom effectiveness and safety must be shown in the clini-
cal setting. Preclinical data can be used to guide the selection of a tentative dose for clinical use
which can then be tested in clinical trials, as previously successfully attempted for a monospe-
cific and trispecific antivenom [33]. However, it is worth stressing that predicting appropriate
therapeutic doses of antivenom for use in snakebite victims from preclinical efficacy ED50 data
is exceedingly problematic. This is due to the fact that in the standard ED50 preclinical assay,
venom is delivered intravenously, a scenario which happens rarely during a snakebite, and
already pre-incubated with antivenom, which does not happen in the real-world. Thus, while
these experiments remain useful for assessing the preclinical efficacy of an antivenom, and for
providing potency comparisons between different products, the model remains exceedingly
limited in terms of representing a ‘real-world’ envenomation scenario. For this reason, in
recent years, a number of groups have moved towards the use of “rescue” experiments, where
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venom is often delivered by different routes and treatment is administered after the onset of
envenomation [66–69]. However, it is clear that to use preclinical data to more rationally and
precisely model the therapeutic doses required to effect cure, a more comprehensive under-
standing of the following is needed; i) the relative amount of toxin-neutralising antibodies in
antivenom products, such as provided by antivenomic analyses [16], ii) the amount and type
of venom toxins circulating in snakebite victims over the time course of an envenoming and in
different tissue compartments and iii) the concentrations of antivenom required to bind and
inhibit the pathogenicity of venom toxins in that time frame and tissue compartment. Such
pharmacodynamic data is routine for the majority of licensed therapeutics that have success-
fully progressed through normal clinical-trial processes[70]. Even with the advancement of
antivenom preclinical testing to more closely match real-life envenoming, all antivenoms must
ultimately still be tested in clinical trials.
3. Greater investment in preclinical testing of antivenoms is required to
maximise their utility to all stakeholders
This analysis of the variation in the reports of, and protocols used for, preclinical antivenom
efficacy testing in sub-Saharan Africa has identified several issues that can be readily remedied,
including:
• Publication of results in formats and journals that maximise access
• Adherence to standard protocols for assessing venom LD50 and antivenom ED50 values
• Standardisation of LD50 challenge doses
• Utilisation of a single metric for reporting antivenom ED50 values–we recommend μl/mg
• Transparent, detailed reporting of preclinical outcomes to allow independent analysis, inter-
pretation and robust peer-review of antivenom ED50 values
• Agreement on acceptable 95% CI ranges for antivenoms
• Transparent reporting of antivenom concentration, experiment duration (hours), venoms
used for immunisation–especially their precise country of origin, and other protocols
The simplest way for these beneficial changes to be implemented would be for the WHO and
relevant journals to adopt and encourage use of a reporting checklist, like the one presented here
(S4 File). Failing that, the WHO guidelines should at a minimum promote the use of reporting
antivenom preclinical efficacy in academic journals using the ARRIVE guidelines, whilst relevant
journals should make concerted efforts in enforcing its use for reporting such studies.
Perhaps the most important outcome of this analysis is the very obvious and urgent need
for more rigorous and comprehensive preclinical testing of antivenoms designed for sub-Saha-
ran Africa. These need to encompass the above points and include a diversity of medically-rel-
evant venoms from geographically diverse countries. Achieving this will require significant
investment from national and international agencies. It will also need a strategy to prevent
breaches of the Nagoya protocol, which forbids the unprotected movement of biological mate-
rial from its country of origin. The most effective, capacity strengthening (but expensive) solu-
tion is the establishment of manufacturer-independent antivenom preclinical testing units in
key locations throughout sub-Saharan Africa. These would provide regional venom resources,
prevent use of antivenoms of questionable efficacy and provide the expertise and knowledge
needed for regional antivenom clinical trials. Investment in this infrastructure will have lasting
benefits to human health.
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